A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab
Asaad Abdelhalim, Orhan Yilmaz, Mohamed Elshaikh Berair, Tiago Torres · 2024
Read A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab by Asaad Abdelhalim, Orhan Yilmaz, Mohamed Elshaikh Berair, Tiago Torres (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11604912.txt.
Description
Asaad Abdelhalim and three colleagues review a new drug strategy for eczema that targets the OX40 immune pathway rather than the usual allergy signals. Two antibody drugs, one blocking the OX40 receptor and one its partner ligand, have been tested in moderate-to-severe atopic dermatitis.
Both beat placebo on skin clearance and symptom reduction in trials, with favorable safety and no serious treatment-related harms so far. Because the pathway shapes T-cell memory, benefits might outlast dosing, though long-term durability and safety remain unproven. The authors present the pair as promising new options for patients poorly served by existing therapies, pending ongoing trials.
Catalog record
| CREATOR | Asaad Abdelhalim, Orhan Yilmaz, Mohamed Elshaikh Berair, Tiago Torres |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |